Ensuring safety of novel oral anticoagulants predictable dose response relationship

Atrial fibrillation (AF) is also the most common cause of cerebrovascular morbidity and mortality in cardioembolic stroke patients. In patients with AF, oral anticoagulation treatment has shown to minimise the risk of cardioembolic stroke by more than half. Anticoagulation with vitamin K antagonists is best used with strict adherence and monitoring. Patient dissatisfaction can be caused by a number of causes, all of which lower the patient's excellence of life. New immediate oral anticoagulants, for example, the immediate factor Xa inhibitors apixaban, edoxaban, and rivaroxaban, and the dabigatran thrombin inhibitor, were intended to defeat the shortcomings of conventional anticoagulant drugs. However, models to boost the estimation of treatment and guarantee that treatment can be securely proceeded are missing for existing oral anticoagulants. This survey will briefly examine the new oral anticoagulants dabigatran, apixaban, edoxaban, and rivaroxaban, with an attention on their utilization in the anticipation of embolic events in AF. It will look at the benefits for patients of life, just as the protection and adequacy of the treatment.